SCHEMBL22441865

SCHEMBL22441865

O=C(C=Cc1cccc(NC(=O)c2cccc(C(F)(F)F)c2)c1)Nc1cccc2cccnc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
MAPT P10636 4/20 0.55
LMNA P02545 2/20 0.55
HSP90AA1 P07900 1/20 0.55
PKM P14618 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
MAOB P27338 1/20 0.52
KDM4E B2RXH2 3/20 0.51
BRAF P15056 2/20 0.51
RXFP1 Q9HBX9 1/20 0.49
KCNK3 O14649 1/20 0.49
HDAC4 P56524 1/20 0.49
MEF2D Q14814 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
RAB9A P51151 2/20 0.48
TSHR P16473 1/20 0.48
NPC1 O15118 1/20 0.48
RECQL P46063 2/20 0.48
POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22441862 1.00 MEN1 (0.55) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22441734 0.96 MAPT (0.58) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22441731 0.96 MAPT (0.58) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22441628 0.85 SLC40A1 (0.63) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22441726 0.83 SLC40A1 (0.61) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL30733198 0.83 RAB9A (0.67) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL28249147 0.83 RAB9A (0.67) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL22441788 0.82 KDM4E (0.50) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22441815 0.82 MEN1 (0.60) MEN1KMT2AMAPTLMNAHSP90AA1
SCHEMBL22441811 0.82 MEN1 (0.60) MEN1KMT2AMAPTLMNAHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200299282-A1 COMPOUNDS AND METHODS FOR TREATING CANCER ANTIDOTE IP HOLDINGS LLC (US) 2020-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200299282-A1 COMPOUNDS AND METHODS FOR TREATING CANCER VHL, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MEN1 364/4885KMT2A 702/4885MAPT 3913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.